[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYNN8kuoyOT5DNCd7_L4rz37FTb7lIhy72vu-d-fpj9w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":61,"rows":68},"GE Healthcare",[4],166,false,16,21,28681,7,102,[14,17,20,23,25,28,30,32],{"name":15,"count":16},"Breast Cancer",15,{"name":18,"count":19},"Coronary Artery Disease",11,{"name":21,"count":22},"Blood Pressure",6,{"name":24,"count":22},"Healthy",{"name":26,"count":27},"Traumatic Brain Injury",4,{"name":29,"count":27},"Alzheimer's Disease",{"name":31,"count":27},"Coronary Artery Disease (CAD)",{"name":33,"count":34},"Tumors, Breast",3,[36,41,46,51,56],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05486182","Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer","2025-04-18","18F Fluoroestradiol Radiopharmaceutical with PET\u002FCT",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04604782","A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients","2026-12","Regadenoson",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT07472491","A Phase 2\u002F3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients","2027-11-30","Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol\u002FmL",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05629689","A Study to Evaluate GEH200520\u002FGEH200521 (18F) Safety and Tolerability When Used for PET Scans in Patients With Solid Tumour Malignancies","2029-03-10","GEH200520 Injection \u002F GEH200521 (18F) Injection - Part A",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07219238","Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET\u002FCT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)","2029-06","GEH300079",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,105,129,147,172,193,216,234,281,318,354,376,402,427,452,470,497,515,539,557,584,602,620,645,663,686,739,783,817,849,885,924,942,968,986,1004,1031,1054,1079,1097,1123,1141,1172,1196,1225,1249,1271,1295,1313,1331,1354,1379,1406,1431,1455,1481,1505,1527,1578,1610,1632,1657],{"intervention":40,"totalTrials":70,"cells":71},2,{"EARLY_PHASE1":72,"PHASE1":75,"PHASE2":77,"PHASE3":79,"PHASE4":81,"NA":93},{"trials":73,"activeCount":74},[],0,{"trials":76,"activeCount":74},[],{"trials":78,"activeCount":74},[],{"trials":80,"activeCount":74},[],{"trials":82,"activeCount":92,"soonestReadout":39},[83],{"nctId":37,"briefTitle":38,"status":84,"phases":85,"primaryCompletion":39,"completion":86,"start":87,"enrollment":88,"conditions":89,"interventions":91},"ACTIVE_NOT_RECRUITING",[66],"2026-01","2022-02-08",153,[90],"Metastatic Breast Cancer",[40],1,{"trials":94,"activeCount":74},[95],{"nctId":96,"briefTitle":97,"status":98,"phases":99,"primaryCompletion":100,"completion":100,"start":101,"enrollment":102,"conditions":103,"interventions":104},"NCT05068726","Clinical Utility of FES F18 PET\u002FCT in Metastatic Breast Cancer Patients","TERMINATED",[],"2024-06-01","2023-01-05",51,[90],[40],{"intervention":50,"totalTrials":92,"cells":106},{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":125,"NA":127},{"trials":108,"activeCount":74},[],{"trials":110,"activeCount":74},[],{"trials":112,"activeCount":74},[],{"trials":114,"activeCount":92,"soonestReadout":49},[115],{"nctId":47,"briefTitle":48,"status":116,"phases":117,"primaryCompletion":49,"completion":49,"start":118,"enrollment":119,"conditions":120,"interventions":123},"RECRUITING",[64,65],"2026-04-01",640,[121,122],"Known or Highly Suspected Central Nervous System (CNS) Lesion","Known or Highly Suspected Body (Excluding CNS) Lesion",[50,124],"Gadobutrol",{"trials":126,"activeCount":74},[],{"trials":128,"activeCount":74},[],{"intervention":124,"totalTrials":92,"cells":130},{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":143,"NA":145},{"trials":132,"activeCount":74},[],{"trials":134,"activeCount":74},[],{"trials":136,"activeCount":74},[],{"trials":138,"activeCount":92,"soonestReadout":49},[139],{"nctId":47,"briefTitle":48,"status":116,"phases":140,"primaryCompletion":49,"completion":49,"start":118,"enrollment":119,"conditions":141,"interventions":142},[64,65],[121,122],[50,124],{"trials":144,"activeCount":74},[],{"trials":146,"activeCount":74},[],{"intervention":60,"totalTrials":92,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":168,"NA":170},{"trials":150,"activeCount":74},[],{"trials":152,"activeCount":74},[],{"trials":154,"activeCount":74},[],{"trials":156,"activeCount":92,"soonestReadout":59},[157],{"nctId":57,"briefTitle":58,"status":116,"phases":158,"primaryCompletion":59,"completion":159,"start":160,"enrollment":161,"conditions":162,"interventions":167},[64,65],"2029-08","2026-05",175,[163,164,165,166],"Colorectal Cancer","Gastric Cancers","Ovarian Cancers","Pancreatic Ductal Adenocarcinoma",[60],{"trials":169,"activeCount":74},[],{"trials":171,"activeCount":74},[],{"intervention":45,"totalTrials":92,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":187,"PHASE4":189,"NA":191},{"trials":175,"activeCount":74},[],{"trials":177,"activeCount":74},[],{"trials":179,"activeCount":92,"soonestReadout":44},[180],{"nctId":42,"briefTitle":43,"status":116,"phases":181,"primaryCompletion":44,"completion":44,"start":182,"enrollment":183,"conditions":184,"interventions":186},[63,64],"2021-05-20",54,[185,18],"Myocardial Ischemia",[45],{"trials":188,"activeCount":74},[],{"trials":190,"activeCount":74},[],{"trials":192,"activeCount":74},[],{"intervention":55,"totalTrials":92,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":208,"PHASE3":210,"PHASE4":212,"NA":214},{"trials":196,"activeCount":74},[],{"trials":198,"activeCount":92,"soonestReadout":54},[199],{"nctId":52,"briefTitle":53,"status":116,"phases":200,"primaryCompletion":54,"completion":54,"start":201,"enrollment":202,"conditions":203,"interventions":206},[63],"2023-01-27",50,[204,205],"Malignant Solid Tumor","Oncology",[55,207],"GEH200520 Injection \u002F GEH200521 (18F) Injection - Part B",{"trials":209,"activeCount":74},[],{"trials":211,"activeCount":74},[],{"trials":213,"activeCount":74},[],{"trials":215,"activeCount":74},[],{"intervention":207,"totalTrials":92,"cells":217},{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":226,"PHASE3":228,"PHASE4":230,"NA":232},{"trials":219,"activeCount":74},[],{"trials":221,"activeCount":92,"soonestReadout":54},[222],{"nctId":52,"briefTitle":53,"status":116,"phases":223,"primaryCompletion":54,"completion":54,"start":201,"enrollment":202,"conditions":224,"interventions":225},[63],[204,205],[55,207],{"trials":227,"activeCount":74},[],{"trials":229,"activeCount":74},[],{"trials":231,"activeCount":74},[],{"trials":233,"activeCount":74},[],{"intervention":235,"totalTrials":34,"cells":236},"Optison",{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":252,"PHASE4":254,"NA":279},{"trials":238,"activeCount":74},[],{"trials":240,"activeCount":74},[],{"trials":242,"activeCount":74},[243],{"nctId":244,"briefTitle":245,"status":98,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":9,"conditions":249,"interventions":251},"NCT01394926","Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U\u002FS for the Detection of Carotid Artery Disease",[64],"2012-06","2011-06",[250],"Carotid Artery Disease",[235],{"trials":253,"activeCount":74},[],{"trials":255,"activeCount":74},[256,268],{"nctId":257,"briefTitle":258,"status":259,"phases":260,"primaryCompletion":261,"completion":261,"start":262,"enrollment":263,"conditions":264,"interventions":267},"NCT03740997","Study to Determine Safety and Dosage of OPTISON in Pediatric Participants","COMPLETED",[66],"2023-03-30","2020-12-01",39,[265,266],"Transthoracic Echocardiography","Suspected or Known Structural or Functional Cardiac Abnormality",[235],{"nctId":269,"briefTitle":270,"status":259,"phases":271,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":275,"interventions":277},"NCT00878878","Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).",[66],"2010-07","2009-03",30,[276],"Pulmonary Hypertension",[235,278],"Dextrose",{"trials":280,"activeCount":74},[],{"intervention":282,"totalTrials":70,"cells":283},"Visipaque",{"EARLY_PHASE1":284,"PHASE1":286,"PHASE2":288,"PHASE3":301,"PHASE4":303,"NA":316},{"trials":285,"activeCount":74},[],{"trials":287,"activeCount":74},[],{"trials":289,"activeCount":74},[290],{"nctId":291,"briefTitle":292,"status":259,"phases":293,"primaryCompletion":294,"completion":295,"start":296,"enrollment":202,"conditions":297,"interventions":298},"NCT01004770","Single Dose Safety, Tolerance and Pharmacokinetic Study in Healthy Volunteers Undergoing Contrast-enhanced Abdominal Computed Tomography (CT)",[63,64],"2010-02","2010-05","2009-10",[24],[299,300],"GE-145 (AN113111)","Visipaque (iodixanol)",{"trials":302,"activeCount":74},[],{"trials":304,"activeCount":74},[305],{"nctId":306,"briefTitle":307,"status":98,"phases":308,"primaryCompletion":309,"completion":310,"start":311,"enrollment":27,"conditions":312,"interventions":314},"NCT03119662","A Study to Explore the Renal Safety of Visipaque Injection 320 mgI\u002FmL in Patients With Chronic Kidney Disease",[66],"2018-09-13","2018-10-19","2018-02-08",[313],"Chronic Kidney Diseases",[282,315],"Placebos",{"trials":317,"activeCount":74},[],{"intervention":319,"totalTrials":70,"cells":320},"Iopamidol",{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":329,"NA":352},{"trials":322,"activeCount":74},[],{"trials":324,"activeCount":74},[],{"trials":326,"activeCount":74},[],{"trials":328,"activeCount":74},[],{"trials":330,"activeCount":74},[331,342],{"nctId":332,"briefTitle":333,"status":259,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT01475097","Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography",[66],"2013-02","2011-10",255,[339],"Drug Safety",[341,319],"Iodixanol",{"nctId":343,"briefTitle":344,"status":259,"phases":345,"primaryCompletion":336,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":351},"NCT01376089","Iodixanol Versus Iopamidol in Patients Undergoing Contrast-Enhanced Computed Tomographic Imaging of Abdomen\u002FPelvis",[66],"2012-02","2011-05",304,[350],"Patient Comfort and Safety",[341,319],{"trials":353,"activeCount":74},[],{"intervention":355,"totalTrials":92,"cells":356},"Iodixanol 320 mg I\u002FMl",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":365,"NA":374},{"trials":358,"activeCount":74},[],{"trials":360,"activeCount":74},[],{"trials":362,"activeCount":74},[],{"trials":364,"activeCount":74},[],{"trials":366,"activeCount":74},[367],{"nctId":368,"briefTitle":369,"status":259,"phases":370,"start":371,"enrollment":202,"conditions":372,"interventions":373},"NCT00209404","Iodixanol in Multidetector-Row Computed Tomography-Coronary Angiography (MDCT-CA)",[66],"2005-07",[18],[355],{"trials":375,"activeCount":74},[],{"intervention":377,"totalTrials":92,"cells":378},"AdreView",{"EARLY_PHASE1":379,"PHASE1":381,"PHASE2":383,"PHASE3":385,"PHASE4":387,"NA":400},{"trials":380,"activeCount":74},[],{"trials":382,"activeCount":74},[],{"trials":384,"activeCount":74},[],{"trials":386,"activeCount":74},[],{"trials":388,"activeCount":74},[389],{"nctId":390,"briefTitle":391,"status":259,"phases":392,"primaryCompletion":393,"completion":393,"start":394,"enrollment":395,"conditions":396,"interventions":399},"NCT01936649","Open-label, Test-retest Study Assessing Reproducibility of Quantitative Measurements of Myocardial Uptake of AdreView.",[66],"2014-02","2013-08",63,[397,398],"Heart Failure (HF)","Ventricular Dysfunction, Left",[377],{"trials":401,"activeCount":74},[],{"intervention":403,"totalTrials":92,"cells":404},"Iodixanol, Ioversol, Iopromide",{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":411,"PHASE4":413,"NA":425},{"trials":406,"activeCount":74},[],{"trials":408,"activeCount":74},[],{"trials":410,"activeCount":74},[],{"trials":412,"activeCount":74},[],{"trials":414,"activeCount":74},[415],{"nctId":416,"briefTitle":417,"status":418,"phases":419,"start":420,"enrollment":74,"conditions":421,"interventions":424},"NCT00335101","Renal Effects of Three Iodinated Contrast Media (CM) in Patients at Risk Undergoing Coronary Angiography","WITHDRAWN",[66],"2006-06",[31,422,423],"Renal Impairment","Diabetes Mellitus",[403],{"trials":426,"activeCount":74},[],{"intervention":428,"totalTrials":92,"cells":429},"Technetium Tc99m Tetrofosmin injections",{"EARLY_PHASE1":430,"PHASE1":432,"PHASE2":434,"PHASE3":436,"PHASE4":438,"NA":450},{"trials":431,"activeCount":74},[],{"trials":433,"activeCount":74},[],{"trials":435,"activeCount":74},[],{"trials":437,"activeCount":74},[],{"trials":439,"activeCount":74},[440],{"nctId":441,"briefTitle":442,"status":259,"phases":443,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":448},"NCT00381316","Comparison of Diagnostic Rest\u002FStress SPECT Results for Patients With Myocardial Ischemia and Infarction Using Myoview in Both Single and Dual Isotope Acquisition Approaches",[66],"2006-12","2006-07",291,[18],[428,449],"Thallous Chloride T1-201",{"trials":451,"activeCount":74},[],{"intervention":449,"totalTrials":92,"cells":453},{"EARLY_PHASE1":454,"PHASE1":456,"PHASE2":458,"PHASE3":460,"PHASE4":462,"NA":468},{"trials":455,"activeCount":74},[],{"trials":457,"activeCount":74},[],{"trials":459,"activeCount":74},[],{"trials":461,"activeCount":74},[],{"trials":463,"activeCount":74},[464],{"nctId":441,"briefTitle":442,"status":259,"phases":465,"completion":444,"start":445,"enrollment":446,"conditions":466,"interventions":467},[66],[18],[428,449],{"trials":469,"activeCount":74},[],{"intervention":471,"totalTrials":92,"cells":472},"Omniscan",{"EARLY_PHASE1":473,"PHASE1":475,"PHASE2":477,"PHASE3":479,"PHASE4":481,"NA":495},{"trials":474,"activeCount":74},[],{"trials":476,"activeCount":74},[],{"trials":478,"activeCount":74},[],{"trials":480,"activeCount":74},[],{"trials":482,"activeCount":74},[483],{"nctId":484,"briefTitle":485,"status":259,"phases":486,"primaryCompletion":487,"completion":488,"start":489,"enrollment":490,"conditions":491,"interventions":494},"NCT00908310","Post-marketing Safety Study in Patients With Moderate Renal Insufficiency Who Receive Omniscan for Contrast-enhanced Magnetic Resonance Imaging (MRI)",[66],"2013-06","2013-09","2009-05",213,[492,493],"Chronic Kidney Disease","Renal Insufficiency",[471],{"trials":496,"activeCount":74},[],{"intervention":315,"totalTrials":92,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":505,"PHASE4":507,"NA":513},{"trials":500,"activeCount":74},[],{"trials":502,"activeCount":74},[],{"trials":504,"activeCount":74},[],{"trials":506,"activeCount":74},[],{"trials":508,"activeCount":74},[509],{"nctId":306,"briefTitle":307,"status":98,"phases":510,"primaryCompletion":309,"completion":310,"start":311,"enrollment":27,"conditions":511,"interventions":512},[66],[313],[282,315],{"trials":514,"activeCount":74},[],{"intervention":516,"totalTrials":92,"cells":517},"Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia",{"EARLY_PHASE1":518,"PHASE1":520,"PHASE2":522,"PHASE3":524,"PHASE4":526,"NA":537},{"trials":519,"activeCount":74},[],{"trials":521,"activeCount":74},[],{"trials":523,"activeCount":74},[],{"trials":525,"activeCount":74},[],{"trials":527,"activeCount":74},[528],{"nctId":529,"briefTitle":530,"status":259,"phases":531,"primaryCompletion":296,"completion":296,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT00730964","A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice.",[66],"2008-05",1039,[535],"Echocardiography",[516],{"trials":538,"activeCount":74},[],{"intervention":278,"totalTrials":92,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":547,"PHASE4":549,"NA":555},{"trials":542,"activeCount":74},[],{"trials":544,"activeCount":74},[],{"trials":546,"activeCount":74},[],{"trials":548,"activeCount":74},[],{"trials":550,"activeCount":74},[551],{"nctId":269,"briefTitle":270,"status":259,"phases":552,"primaryCompletion":272,"completion":272,"start":273,"enrollment":274,"conditions":553,"interventions":554},[66],[276],[235,278],{"trials":556,"activeCount":74},[],{"intervention":558,"totalTrials":92,"cells":559},"Iohexol",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":582},{"trials":561,"activeCount":74},[],{"trials":563,"activeCount":74},[],{"trials":565,"activeCount":74},[],{"trials":567,"activeCount":74},[],{"trials":569,"activeCount":74},[570],{"nctId":571,"briefTitle":572,"status":418,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":74,"conditions":577,"interventions":579},"NCT03631771","Pediatric Risk of Hypothyroidism With Iodinated Contrast Media",[66],"2024-08","2025-02","2022-03",[578],"Hypothyroidism",[558,341,580,581],"Iopromide","Ioversol",{"trials":583,"activeCount":74},[],{"intervention":580,"totalTrials":92,"cells":585},{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":600},{"trials":587,"activeCount":74},[],{"trials":589,"activeCount":74},[],{"trials":591,"activeCount":74},[],{"trials":593,"activeCount":74},[],{"trials":595,"activeCount":74},[596],{"nctId":571,"briefTitle":572,"status":418,"phases":597,"primaryCompletion":574,"completion":575,"start":576,"enrollment":74,"conditions":598,"interventions":599},[66],[578],[558,341,580,581],{"trials":601,"activeCount":74},[],{"intervention":581,"totalTrials":92,"cells":603},{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":618},{"trials":605,"activeCount":74},[],{"trials":607,"activeCount":74},[],{"trials":609,"activeCount":74},[],{"trials":611,"activeCount":74},[],{"trials":613,"activeCount":74},[614],{"nctId":571,"briefTitle":572,"status":418,"phases":615,"primaryCompletion":574,"completion":575,"start":576,"enrollment":74,"conditions":616,"interventions":617},[66],[578],[558,341,580,581],{"trials":619,"activeCount":74},[],{"intervention":621,"totalTrials":92,"cells":622},"Iodixanol 320-Arm 1",{"EARLY_PHASE1":623,"PHASE1":625,"PHASE2":627,"PHASE3":629,"PHASE4":631,"NA":643},{"trials":624,"activeCount":74},[],{"trials":626,"activeCount":74},[],{"trials":628,"activeCount":74},[],{"trials":630,"activeCount":74},[],{"trials":632,"activeCount":74},[633],{"nctId":634,"briefTitle":635,"status":98,"phases":636,"primaryCompletion":347,"completion":637,"start":638,"enrollment":639,"conditions":640,"interventions":641},"NCT00209417","Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Computed Tomography",[66],"2011-07","2005-06",656,[493,423],[621,642],"Iopamidol 300-Arm 2",{"trials":644,"activeCount":74},[],{"intervention":642,"totalTrials":92,"cells":646},{"EARLY_PHASE1":647,"PHASE1":649,"PHASE2":651,"PHASE3":653,"PHASE4":655,"NA":661},{"trials":648,"activeCount":74},[],{"trials":650,"activeCount":74},[],{"trials":652,"activeCount":74},[],{"trials":654,"activeCount":74},[],{"trials":656,"activeCount":74},[657],{"nctId":634,"briefTitle":635,"status":98,"phases":658,"primaryCompletion":347,"completion":637,"start":638,"enrollment":639,"conditions":659,"interventions":660},[66],[493,423],[621,642],{"trials":662,"activeCount":74},[],{"intervention":664,"totalTrials":92,"cells":665},"Iodixanol 320 mgI\u002FmL",{"EARLY_PHASE1":666,"PHASE1":668,"PHASE2":670,"PHASE3":672,"PHASE4":674,"NA":684},{"trials":667,"activeCount":74},[],{"trials":669,"activeCount":74},[],{"trials":671,"activeCount":74},[],{"trials":673,"activeCount":74},[],{"trials":675,"activeCount":74},[676],{"nctId":677,"briefTitle":678,"status":259,"phases":679,"start":680,"enrollment":681,"conditions":682,"interventions":683},"NCT00209430","Renal Effects of Two Iodinated Contrast Media in Patients at Risk Undergoing Coronary Angiography",[66],"2005-08",408,[18,422],[664],{"trials":685,"activeCount":74},[],{"intervention":687,"totalTrials":27,"cells":688},"[18F] Flutemetamol",{"EARLY_PHASE1":689,"PHASE1":691,"PHASE2":693,"PHASE3":705,"PHASE4":735,"NA":737},{"trials":690,"activeCount":74},[],{"trials":692,"activeCount":74},[],{"trials":694,"activeCount":74},[695],{"nctId":696,"briefTitle":697,"status":259,"phases":698,"primaryCompletion":699,"completion":699,"start":700,"enrollment":701,"conditions":702,"interventions":704},"NCT02813070","Comparison of PET Amyloid Imaging in Japanese and Western Subjects",[64],"2013-05","2012-10",70,[703,29,24],"Mild Cognitive Impairment",[687],{"trials":706,"activeCount":74},[707,716,725],{"nctId":708,"briefTitle":709,"status":259,"phases":710,"primaryCompletion":272,"completion":711,"start":712,"enrollment":11,"conditions":713,"interventions":715},"NCT01053312","PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus",[65],"2010-08","2009-12",[714],"Normal Pressure Hydrocephalus",[687],{"nctId":717,"briefTitle":718,"status":259,"phases":719,"primaryCompletion":720,"completion":720,"start":295,"enrollment":721,"conditions":722,"interventions":724},"NCT01165554","Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels",[65],"2011-11",203,[723],"Brain Fibrillarab Levels",[687],{"nctId":726,"briefTitle":727,"status":259,"phases":728,"primaryCompletion":729,"completion":730,"start":731,"enrollment":732,"conditions":733,"interventions":734},"NCT01265394","Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects",[65],"2011-03","2011-04","2010-12",218,[24],[687],{"trials":736,"activeCount":74},[],{"trials":738,"activeCount":74},[],{"intervention":740,"totalTrials":34,"cells":741},"123I-mIBG",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":748,"PHASE4":779,"NA":781},{"trials":743,"activeCount":74},[],{"trials":745,"activeCount":74},[],{"trials":747,"activeCount":74},[],{"trials":749,"activeCount":74},[750,761,771],{"nctId":751,"briefTitle":752,"status":259,"phases":753,"primaryCompletion":754,"completion":754,"start":755,"enrollment":756,"conditions":757,"interventions":760},"NCT00126412","Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma",[65],"2006-09-27","2005-08-02",251,[758,759],"Pheochromocytoma","Neuroblastoma",[740],{"nctId":762,"briefTitle":763,"status":259,"phases":764,"primaryCompletion":765,"completion":766,"start":371,"enrollment":767,"conditions":768,"interventions":770},"NCT00126425","Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease",[65],"2008-07","2008-12",587,[769],"Heart Failure, Congestive",[740],{"nctId":772,"briefTitle":773,"status":259,"phases":774,"primaryCompletion":765,"completion":775,"start":371,"enrollment":776,"conditions":777,"interventions":778},"NCT00126438","Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease",[65],"2008-09",515,[769],[740],{"trials":780,"activeCount":74},[],{"trials":782,"activeCount":74},[],{"intervention":784,"totalTrials":70,"cells":785},"Sonazoid™",{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":798,"PHASE3":800,"PHASE4":813,"NA":815},{"trials":787,"activeCount":74},[],{"trials":789,"activeCount":74},[790],{"nctId":791,"briefTitle":792,"status":259,"phases":793,"primaryCompletion":794,"completion":794,"start":795,"enrollment":8,"conditions":796,"interventions":797},"NCT03340870","A Study to Evaluate Pharmacokinetics of Sonazoid™ Following Intravenous Bolus Injection in Healthy Volunteers",[63],"2014-11-20","2014-10-20",[24],[784],{"trials":799,"activeCount":74},[],{"trials":801,"activeCount":74},[802],{"nctId":803,"briefTitle":804,"status":259,"phases":805,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":809,"interventions":811},"NCT03335566","An Efficacy and Safety Study of Sonazoid™ and SonoVue® in Participants With Focal Liver Lesions, Undergoing Pre- and Post-Contrast Ultrasound Imaging",[65],"2015-04-09","2014-05-11",424,[810],"Liver Lesions",[784,812],"SonoVue®",{"trials":814,"activeCount":74},[],{"trials":816,"activeCount":74},[],{"intervention":818,"totalTrials":70,"cells":819},"[18F]Flutemetamol",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":845,"NA":847},{"trials":821,"activeCount":74},[],{"trials":823,"activeCount":74},[],{"trials":825,"activeCount":74},[],{"trials":827,"activeCount":74},[828,836],{"nctId":829,"briefTitle":830,"status":98,"phases":831,"primaryCompletion":730,"completion":730,"start":832,"enrollment":833,"conditions":834,"interventions":835},"NCT01092546","Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus",[65],"2010-03",12,[714],[818],{"nctId":837,"briefTitle":838,"status":259,"phases":839,"primaryCompletion":840,"completion":840,"start":841,"enrollment":842,"conditions":843,"interventions":844},"NCT01672827","Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images",[65],"2012-08","2012-07",276,[29,703],[818],{"trials":846,"activeCount":74},[],{"trials":848,"activeCount":74},[],{"intervention":850,"totalTrials":70,"cells":851},"Gadodiamide",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":858,"PHASE4":881,"NA":883},{"trials":853,"activeCount":74},[],{"trials":855,"activeCount":74},[],{"trials":857,"activeCount":74},[],{"trials":859,"activeCount":74},[860,870],{"nctId":861,"briefTitle":862,"status":259,"phases":863,"primaryCompletion":864,"completion":864,"start":865,"enrollment":866,"conditions":867,"interventions":869},"NCT00209391","A Safety & Efficacy Clinical Study to Evaluate the Narrowing of the Renal Arteries While Using Gadodiamide",[65],"2005-08-01","2003-09",395,[868],"Renal Artery Stenosis",[850],{"nctId":871,"briefTitle":872,"status":259,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":880},"NCT00209443","A Safety and Efficacy Clinical Study to Evaluate the Narrowing of the Aorto-iliac Arteries While Using Gadodiamide",[65],"2006-02-28","2004-09",407,[878,879],"Aorto-iliac Stenosis","Arterial Occlusive Diseases",[850],{"trials":882,"activeCount":74},[],{"trials":884,"activeCount":74},[],{"intervention":886,"totalTrials":70,"cells":887},"DaTSCAN™ Ioflupane (123I)",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":902,"PHASE3":904,"PHASE4":920,"NA":922},{"trials":889,"activeCount":74},[],{"trials":891,"activeCount":74},[892],{"nctId":893,"briefTitle":894,"status":259,"phases":895,"primaryCompletion":896,"completion":896,"start":897,"enrollment":898,"conditions":899,"interventions":901},"NCT04564092","A Study to Evaluate the Safety, Biodistribution, Internal Radiation Dosimetry, and Effective Dose of DaTSCAN™ Ioflupane (123I) Injection in Chinese Healthy Volunteers.",[63],"2021-09-04","2021-05-13",9,[900],"Healthy Subjects (HS)",[886],{"trials":903,"activeCount":74},[],{"trials":905,"activeCount":74},[906],{"nctId":907,"briefTitle":908,"status":259,"phases":909,"primaryCompletion":910,"completion":910,"start":911,"enrollment":912,"conditions":913,"interventions":919},"NCT04193527","A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients",[65],"2021-12-20","2020-06-28",172,[914,915,916,917,918],"Parkinsonian Syndrome","Parkinson Disease(PD)","Multiple System Atrophy (MSA)","Progressive Supranuclear Palsy (PSP)","Essential Tremor",[886],{"trials":921,"activeCount":74},[],{"trials":923,"activeCount":74},[],{"intervention":812,"totalTrials":92,"cells":925},{"EARLY_PHASE1":926,"PHASE1":928,"PHASE2":930,"PHASE3":932,"PHASE4":938,"NA":940},{"trials":927,"activeCount":74},[],{"trials":929,"activeCount":74},[],{"trials":931,"activeCount":74},[],{"trials":933,"activeCount":74},[934],{"nctId":803,"briefTitle":804,"status":259,"phases":935,"primaryCompletion":806,"completion":806,"start":807,"enrollment":808,"conditions":936,"interventions":937},[65],[810],[784,812],{"trials":939,"activeCount":74},[],{"trials":941,"activeCount":74},[],{"intervention":943,"totalTrials":92,"cells":944},"PET MPI",{"EARLY_PHASE1":945,"PHASE1":947,"PHASE2":949,"PHASE3":951,"PHASE4":964,"NA":966},{"trials":946,"activeCount":74},[],{"trials":948,"activeCount":74},[],{"trials":950,"activeCount":74},[],{"trials":952,"activeCount":74},[953],{"nctId":954,"briefTitle":955,"status":259,"phases":956,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":960,"interventions":961},"NCT03354273","An International Study to Evaluate Diagnostic Efficacy of Flurpiridaz (18F) Injection PET MPI in the Detection of Coronary Artery Disease (CAD)",[65],"2022-05-05","2018-06-05",730,[31],[943,962,963],"SPECT MPI","Pharmacological stress agents",{"trials":965,"activeCount":74},[],{"trials":967,"activeCount":74},[],{"intervention":962,"totalTrials":92,"cells":969},{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":982,"NA":984},{"trials":971,"activeCount":74},[],{"trials":973,"activeCount":74},[],{"trials":975,"activeCount":74},[],{"trials":977,"activeCount":74},[978],{"nctId":954,"briefTitle":955,"status":259,"phases":979,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":980,"interventions":981},[65],[31],[943,962,963],{"trials":983,"activeCount":74},[],{"trials":985,"activeCount":74},[],{"intervention":963,"totalTrials":92,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":1000,"NA":1002},{"trials":989,"activeCount":74},[],{"trials":991,"activeCount":74},[],{"trials":993,"activeCount":74},[],{"trials":995,"activeCount":74},[996],{"nctId":954,"briefTitle":955,"status":259,"phases":997,"primaryCompletion":957,"completion":957,"start":958,"enrollment":959,"conditions":998,"interventions":999},[65],[31],[943,962,963],{"trials":1001,"activeCount":74},[],{"trials":1003,"activeCount":74},[],{"intervention":1005,"totalTrials":92,"cells":1006},"DatSCAN",{"EARLY_PHASE1":1007,"PHASE1":1009,"PHASE2":1011,"PHASE3":1013,"PHASE4":1027,"NA":1029},{"trials":1008,"activeCount":74},[],{"trials":1010,"activeCount":74},[],{"trials":1012,"activeCount":74},[],{"trials":1014,"activeCount":74},[1015],{"nctId":1016,"briefTitle":1017,"status":259,"phases":1018,"start":1019,"enrollment":1020,"conditions":1021,"interventions":1026},"NCT00209456","Dopamine Transporter Scintigraphy Imaging (DAT-Imaging) in Patients With Lewy Body Dementia",[65],"2003-11",326,[1022,1023,1024,1025],"Lewy Body Dementia","Non-DLB Dementia","Alzheimer's","Vascular Dementia",[1005],{"trials":1028,"activeCount":74},[],{"trials":1030,"activeCount":74},[],{"intervention":1032,"totalTrials":92,"cells":1033},"Flutemetamol (18F)",{"EARLY_PHASE1":1034,"PHASE1":1036,"PHASE2":1038,"PHASE3":1040,"PHASE4":1050,"NA":1052},{"trials":1035,"activeCount":74},[],{"trials":1037,"activeCount":74},[],{"trials":1039,"activeCount":74},[],{"trials":1041,"activeCount":74},[1042],{"nctId":1043,"briefTitle":1044,"status":259,"phases":1045,"primaryCompletion":1046,"completion":1046,"start":712,"enrollment":1047,"conditions":1048,"interventions":1049},"NCT01028053","Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease",[65],"2014-01",365,[703,29],[1032],{"trials":1051,"activeCount":74},[],{"trials":1053,"activeCount":74},[],{"intervention":1055,"totalTrials":92,"cells":1056},"Iobenguane I -123",{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1063,"PHASE4":1075,"NA":1077},{"trials":1058,"activeCount":74},[],{"trials":1060,"activeCount":74},[],{"trials":1062,"activeCount":74},[],{"trials":1064,"activeCount":74},[1065],{"nctId":1066,"briefTitle":1067,"status":98,"phases":1068,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":866,"conditions":1071,"interventions":1073},"NCT02656329","International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device",[65],"2018-05-04","2015-12-30",[1072],"Heart Failure",[1055,1074,1055],"Thyroid blocking",{"trials":1076,"activeCount":74},[],{"trials":1078,"activeCount":74},[],{"intervention":1074,"totalTrials":92,"cells":1080},{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1087,"PHASE4":1093,"NA":1095},{"trials":1082,"activeCount":74},[],{"trials":1084,"activeCount":74},[],{"trials":1086,"activeCount":74},[],{"trials":1088,"activeCount":74},[1089],{"nctId":1066,"briefTitle":1067,"status":98,"phases":1090,"primaryCompletion":1069,"completion":1069,"start":1070,"enrollment":866,"conditions":1091,"interventions":1092},[65],[1072],[1055,1074,1055],{"trials":1094,"activeCount":74},[],{"trials":1096,"activeCount":74},[],{"intervention":1098,"totalTrials":92,"cells":1099},"SPECT",{"EARLY_PHASE1":1100,"PHASE1":1102,"PHASE2":1104,"PHASE3":1106,"PHASE4":1119,"NA":1121},{"trials":1101,"activeCount":74},[],{"trials":1103,"activeCount":74},[],{"trials":1105,"activeCount":74},[],{"trials":1107,"activeCount":74},[1108],{"nctId":1109,"briefTitle":1110,"status":259,"phases":1111,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1115,"interventions":1117},"NCT04265209","[18F] LBT-999 PET Compared to [123I]-FP\u002FCIT SPECT to Distinguish Between Parkinson's Diseases and Essential Tremor",[65],"2024-08-02","2021-12-01",152,[1116,918],"Parkinson Disease",[1098,1118],"PET",{"trials":1120,"activeCount":74},[],{"trials":1122,"activeCount":74},[],{"intervention":1118,"totalTrials":92,"cells":1124},{"EARLY_PHASE1":1125,"PHASE1":1127,"PHASE2":1129,"PHASE3":1131,"PHASE4":1137,"NA":1139},{"trials":1126,"activeCount":74},[],{"trials":1128,"activeCount":74},[],{"trials":1130,"activeCount":74},[],{"trials":1132,"activeCount":74},[1133],{"nctId":1109,"briefTitle":1110,"status":259,"phases":1134,"primaryCompletion":1112,"completion":1112,"start":1113,"enrollment":1114,"conditions":1135,"interventions":1136},[65],[1116,918],[1098,1118],{"trials":1138,"activeCount":74},[],{"trials":1140,"activeCount":74},[],{"intervention":1142,"totalTrials":70,"cells":1143},"GE-145",{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1166,"PHASE4":1168,"NA":1170},{"trials":1145,"activeCount":74},[],{"trials":1147,"activeCount":74},[],{"trials":1149,"activeCount":74},[1150,1162],{"nctId":1151,"briefTitle":1152,"status":259,"phases":1153,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1161},"NCT01252810","Safety Study of GE-145 320 mg I\u002FmL Injection vs. Iopamidol 370 mg I\u002FmL in Elderly Subjects Undergoing Coronary Procedure",[64],"2012-12","2010-11",284,[1158,1159,1160],"Chronic Renal Insufficiency","Diabete Mellitus","Congestive Heart Failure",[1142],{"nctId":291,"briefTitle":292,"status":259,"phases":1163,"primaryCompletion":294,"completion":295,"start":296,"enrollment":202,"conditions":1164,"interventions":1165},[63,64],[24],[299,300],{"trials":1167,"activeCount":74},[],{"trials":1169,"activeCount":74},[],{"trials":1171,"activeCount":74},[],{"intervention":1173,"totalTrials":92,"cells":1174},"GE-148",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1190,"PHASE4":1192,"NA":1194},{"trials":1176,"activeCount":74},[],{"trials":1178,"activeCount":74},[],{"trials":1180,"activeCount":74},[1181],{"nctId":1182,"briefTitle":1183,"status":98,"phases":1184,"primaryCompletion":1185,"completion":1185,"start":272,"enrollment":1186,"conditions":1187,"interventions":1189},"NCT01176513","GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer",[64],"2012-03",25,[1188],"Prostate Cancer",[1173],{"trials":1191,"activeCount":74},[],{"trials":1193,"activeCount":74},[],{"trials":1195,"activeCount":74},[],{"intervention":1197,"totalTrials":92,"cells":1198},"Fluciclatide",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1200,"activeCount":74},[],{"trials":1202,"activeCount":74},[],{"trials":1204,"activeCount":74},[1205],{"nctId":1206,"briefTitle":1207,"status":259,"phases":1208,"primaryCompletion":1209,"completion":336,"start":1210,"enrollment":701,"conditions":1211,"interventions":1218},"NCT00918281","Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection",[64],"2011-09","2009-06",[1212,1213,1214,1215,1216,1217,15],"Solid Tumors","High Grade Gliomas","Lung Cancer","Head and Neck Cancer","Sarcoma","Renal Cell Carcinoma",[1197],{"trials":1220,"activeCount":74},[],{"trials":1222,"activeCount":74},[],{"trials":1224,"activeCount":74},[],{"intervention":1226,"totalTrials":92,"cells":1227},"Altropane (123I)",{"EARLY_PHASE1":1228,"PHASE1":1230,"PHASE2":1232,"PHASE3":1243,"PHASE4":1245,"NA":1247},{"trials":1229,"activeCount":74},[],{"trials":1231,"activeCount":74},[],{"trials":1233,"activeCount":74},[1234],{"nctId":1235,"briefTitle":1236,"status":98,"phases":1237,"primaryCompletion":1238,"completion":1238,"start":1239,"enrollment":16,"conditions":1240,"interventions":1242},"NCT05636852","Altropane Dose for Imaging Patients With Suspected Parkinson's Disease",[64],"2024-06-08","2023-04-24",[1116,1241],"Movement Disorders",[1226],{"trials":1244,"activeCount":74},[],{"trials":1246,"activeCount":74},[],{"trials":1248,"activeCount":74},[],{"intervention":1250,"totalTrials":92,"cells":1251},"Tc99m-Maraciclatide",{"EARLY_PHASE1":1252,"PHASE1":1254,"PHASE2":1256,"PHASE3":1265,"PHASE4":1267,"NA":1269},{"trials":1253,"activeCount":74},[],{"trials":1255,"activeCount":74},[],{"trials":1257,"activeCount":74},[1258],{"nctId":1259,"briefTitle":1260,"status":98,"phases":1261,"primaryCompletion":1185,"completion":1185,"start":1262,"enrollment":27,"conditions":1263,"interventions":1264},"NCT01440517","Results of Tc99m-Maraciclatide Scintigraphy in Subjects With Diabetes Mellitus and Heart Failure With Preserved Left Ventricular Ejection Fraction",[64],"2011-08",[423,1072],[1250],{"trials":1266,"activeCount":74},[],{"trials":1268,"activeCount":74},[],{"trials":1270,"activeCount":74},[],{"intervention":1272,"totalTrials":92,"cells":1273},"Ioforminol 160 mgI\u002FmL",{"EARLY_PHASE1":1274,"PHASE1":1276,"PHASE2":1278,"PHASE3":1289,"PHASE4":1291,"NA":1293},{"trials":1275,"activeCount":74},[],{"trials":1277,"activeCount":74},[],{"trials":1279,"activeCount":74},[1280],{"nctId":1281,"briefTitle":1282,"status":259,"phases":1283,"primaryCompletion":840,"completion":840,"start":841,"enrollment":1284,"conditions":1285,"interventions":1286},"NCT01672996","Open Label, Randomized Study of Low Concentration Ioforminol Injections for Use in Abdominal CECT in Healthy Volunteers",[63,64],66,[24],[1272,1287,1288],"Ioforminol 200 mgI\u002FmL","Iopamidol 300 mgI\u002FmL",{"trials":1290,"activeCount":74},[],{"trials":1292,"activeCount":74},[],{"trials":1294,"activeCount":74},[],{"intervention":1287,"totalTrials":92,"cells":1296},{"EARLY_PHASE1":1297,"PHASE1":1299,"PHASE2":1301,"PHASE3":1307,"PHASE4":1309,"NA":1311},{"trials":1298,"activeCount":74},[],{"trials":1300,"activeCount":74},[],{"trials":1302,"activeCount":74},[1303],{"nctId":1281,"briefTitle":1282,"status":259,"phases":1304,"primaryCompletion":840,"completion":840,"start":841,"enrollment":1284,"conditions":1305,"interventions":1306},[63,64],[24],[1272,1287,1288],{"trials":1308,"activeCount":74},[],{"trials":1310,"activeCount":74},[],{"trials":1312,"activeCount":74},[],{"intervention":1288,"totalTrials":92,"cells":1314},{"EARLY_PHASE1":1315,"PHASE1":1317,"PHASE2":1319,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1316,"activeCount":74},[],{"trials":1318,"activeCount":74},[],{"trials":1320,"activeCount":74},[1321],{"nctId":1281,"briefTitle":1282,"status":259,"phases":1322,"primaryCompletion":840,"completion":840,"start":841,"enrollment":1284,"conditions":1323,"interventions":1324},[63,64],[24],[1272,1287,1288],{"trials":1326,"activeCount":74},[],{"trials":1328,"activeCount":74},[],{"trials":1330,"activeCount":74},[],{"intervention":1332,"totalTrials":92,"cells":1333},"AH110690 (18F)",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1335,"activeCount":74},[],{"trials":1337,"activeCount":74},[],{"trials":1339,"activeCount":74},[1340],{"nctId":1341,"briefTitle":1342,"status":259,"phases":1343,"primaryCompletion":273,"completion":712,"start":775,"enrollment":1344,"conditions":1345,"interventions":1347},"NCT00785759","Brain Uptake and Safety With Probable Alzheimer's Disease, Amnestic Mild Cognitive Impairment and Healthy Volunteers",[64],78,[29,1346],"Amnestic Mild Cognitive Impairment",[1332],{"trials":1349,"activeCount":74},[],{"trials":1351,"activeCount":74},[],{"trials":1353,"activeCount":74},[],{"intervention":1355,"totalTrials":92,"cells":1356},"Flurpiridaz (18F)",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1373,"PHASE4":1375,"NA":1377},{"trials":1358,"activeCount":74},[],{"trials":1360,"activeCount":74},[],{"trials":1362,"activeCount":74},[1363],{"nctId":1364,"briefTitle":1365,"status":259,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":1368,"enrollment":1369,"conditions":1370,"interventions":1372},"NCT04594941","A Study of Flurpiridaz (18F) Injection for PET Imaging for Assessment of MPI Quality Using HPLC and SPE Manufacturing Processes",[64],"2022-05-26","2022-01-27",38,[31,1371],"Ischemic Heart Disease",[1355],{"trials":1374,"activeCount":74},[],{"trials":1376,"activeCount":74},[],{"trials":1378,"activeCount":74},[],{"intervention":1380,"totalTrials":92,"cells":1381},"Fluciclatide Injection -",{"EARLY_PHASE1":1382,"PHASE1":1384,"PHASE2":1386,"PHASE3":1400,"PHASE4":1402,"NA":1404},{"trials":1383,"activeCount":74},[],{"trials":1385,"activeCount":74},[],{"trials":1387,"activeCount":74},[1388],{"nctId":1389,"briefTitle":1390,"status":259,"phases":1391,"primaryCompletion":336,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1399},"NCT00565721","A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis",[64],"2012-09","2007-11",33,[1396,1214,1397,1216,1398],"High-grade Glioma","Head & Neck Cancer","Melanoma",[1380],{"trials":1401,"activeCount":74},[],{"trials":1403,"activeCount":74},[],{"trials":1405,"activeCount":74},[],{"intervention":1407,"totalTrials":92,"cells":1408},"XRX-001 Inactivated yellow fever vaccine",{"EARLY_PHASE1":1409,"PHASE1":1411,"PHASE2":1423,"PHASE3":1425,"PHASE4":1427,"NA":1429},{"trials":1410,"activeCount":74},[],{"trials":1412,"activeCount":74},[1413],{"nctId":1414,"briefTitle":1415,"status":259,"phases":1416,"primaryCompletion":295,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1422},"NCT00995865","Trial of Yellow Fever Inactivated Vaccine",[63],"2010-10","2010-01",60,[1421],"Yellow Fever",[1407],{"trials":1424,"activeCount":74},[],{"trials":1426,"activeCount":74},[],{"trials":1428,"activeCount":74},[],{"trials":1430,"activeCount":74},[],{"intervention":1432,"totalTrials":92,"cells":1433},"Arm 1 - GEH120714 (18F)",{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1447,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1435,"activeCount":74},[],{"trials":1437,"activeCount":74},[1438],{"nctId":1439,"briefTitle":1440,"status":259,"phases":1441,"primaryCompletion":1442,"completion":1442,"start":1443,"enrollment":274,"conditions":1444,"interventions":1446},"NCT01738347","Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).",[63],"2016-05","2013-04",[1445],"Relapsing-remitting Multiple Sclerosis (rrMS)",[1432],{"trials":1448,"activeCount":74},[],{"trials":1450,"activeCount":74},[],{"trials":1452,"activeCount":74},[],{"trials":1454,"activeCount":74},[],{"intervention":1456,"totalTrials":92,"cells":1457},"GEH200520 Injection and GEH200521 (18F)",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1473,"PHASE3":1475,"PHASE4":1477,"NA":1479},{"trials":1459,"activeCount":74},[],{"trials":1461,"activeCount":74},[1462],{"nctId":1463,"briefTitle":1464,"status":259,"phases":1465,"primaryCompletion":1466,"completion":1467,"start":1468,"enrollment":1469,"conditions":1470,"interventions":1472},"NCT06398730","A Phase 1, Dose-Escalation, Positron Emission Tomography Study to Assess the Safety, Pharmacokinetics, Dosimetry and Biodistribution of GEH200521 (18F) Injection Co-Administered With GEH200520 Injection in Healthy Volunteers",[63],"2026-02-19","2026-02-23","2024-07-02",22,[1471],"Healthy Volunteers",[1456],{"trials":1474,"activeCount":74},[],{"trials":1476,"activeCount":74},[],{"trials":1478,"activeCount":74},[],{"trials":1480,"activeCount":74},[],{"intervention":1482,"totalTrials":92,"cells":1483},"GE200486 0.5M",{"EARLY_PHASE1":1484,"PHASE1":1486,"PHASE2":1497,"PHASE3":1499,"PHASE4":1501,"NA":1503},{"trials":1485,"activeCount":74},[],{"trials":1487,"activeCount":74},[1488],{"nctId":1489,"briefTitle":1490,"status":259,"phases":1491,"primaryCompletion":1492,"completion":1492,"start":1493,"enrollment":16,"conditions":1494,"interventions":1496},"NCT05569278","Safety and Pharmacokinetics of GEH200486 in Healthy Volunteers",[63],"2022-11-29","2022-08-22",[1495],"Pharmacokinetics",[1482],{"trials":1498,"activeCount":74},[],{"trials":1500,"activeCount":74},[],{"trials":1502,"activeCount":74},[],{"trials":1504,"activeCount":74},[],{"intervention":1506,"totalTrials":92,"cells":1507},"GEH121224 (18F)",{"EARLY_PHASE1":1508,"PHASE1":1510,"PHASE2":1519,"PHASE3":1521,"PHASE4":1523,"NA":1525},{"trials":1509,"activeCount":74},[],{"trials":1511,"activeCount":74},[1512],{"nctId":1513,"briefTitle":1514,"status":418,"phases":1515,"primaryCompletion":44,"completion":44,"start":1516,"enrollment":74,"conditions":1517,"interventions":1518},"NCT05634954","Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer",[63],"2026-02",[15],[1506],{"trials":1520,"activeCount":74},[],{"trials":1522,"activeCount":74},[],{"trials":1524,"activeCount":74},[],{"trials":1526,"activeCount":74},[],{"intervention":341,"totalTrials":22,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1552,"NA":1566},{"trials":1530,"activeCount":74},[],{"trials":1532,"activeCount":74},[],{"trials":1534,"activeCount":74},[],{"trials":1536,"activeCount":74},[1537,1547],{"nctId":1538,"briefTitle":1539,"status":98,"phases":1540,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1545},"NCT00335335","Safety and Effectiveness of Visipaque 320mg-I\u002Fml for Use in Contrast-Enhanced CT Angiography of Arteries of the Heart",[65],"2006-12-02","2006-05",89,[18],[1546],"iodixanol",{"nctId":1548,"briefTitle":1539,"status":98,"phases":1549,"primaryCompletion":1541,"completion":1541,"start":420,"enrollment":1284,"conditions":1550,"interventions":1551},"NCT00348608",[65],[18],[1546],{"trials":1553,"activeCount":74},[1554,1558,1562],{"nctId":571,"briefTitle":572,"status":418,"phases":1555,"primaryCompletion":574,"completion":575,"start":576,"enrollment":74,"conditions":1556,"interventions":1557},[66],[578],[558,341,580,581],{"nctId":332,"briefTitle":333,"status":259,"phases":1559,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":1560,"interventions":1561},[66],[339],[341,319],{"nctId":343,"briefTitle":344,"status":259,"phases":1563,"primaryCompletion":336,"completion":346,"start":347,"enrollment":348,"conditions":1564,"interventions":1565},[66],[350],[341,319],{"trials":1567,"activeCount":74},[1568],{"nctId":1569,"briefTitle":1570,"status":259,"phases":1571,"primaryCompletion":1572,"completion":1572,"start":1573,"enrollment":1574,"conditions":1575,"interventions":1577},"NCT03671603","Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium",[],"2021-06-07","2018-11-05",2755,[18,1576],"ST-segment Elevation Myocardial Infarction",[341],{"intervention":1579,"totalTrials":70,"cells":1580},"Hexaminolevulinate",{"EARLY_PHASE1":1581,"PHASE1":1583,"PHASE2":1585,"PHASE3":1587,"PHASE4":1589,"NA":1599},{"trials":1582,"activeCount":74},[],{"trials":1584,"activeCount":74},[],{"trials":1586,"activeCount":74},[],{"trials":1588,"activeCount":74},[],{"trials":1590,"activeCount":74},[1591],{"nctId":1592,"briefTitle":1593,"status":418,"phases":1594,"primaryCompletion":1262,"completion":1262,"start":766,"enrollment":74,"conditions":1595,"interventions":1597},"NCT00785694","Recurrence of Bladder Cancer After Transurethral Resection With Hexvix",[66],[1596],"Bladder Cancer",[1598],"hexaminolevulinate",{"trials":1600,"activeCount":74},[1601],{"nctId":1602,"briefTitle":1603,"status":259,"phases":1604,"primaryCompletion":1605,"completion":1605,"start":1606,"enrollment":1607,"conditions":1608,"interventions":1609},"NCT00634621","Effectiveness of Hexaminolevulinate (Hexvix) in the Diagnosis and Treatment of Patients With Non-invasive Bladder Cancer",[],"2010-09","2008-02",283,[1596],[1579],{"intervention":1611,"totalTrials":92,"cells":1612},"Iobenguane I 123",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1614,"activeCount":74},[],{"trials":1616,"activeCount":74},[],{"trials":1618,"activeCount":74},[],{"trials":1620,"activeCount":74},[],{"trials":1622,"activeCount":74},[],{"trials":1624,"activeCount":74},[1625],{"nctId":1626,"briefTitle":1627,"status":1628,"phases":1629,"conditions":1630,"interventions":1631},"NCT00730444","Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma","APPROVED_FOR_MARKETING",[],[759],[1611],{"intervention":1633,"totalTrials":92,"cells":1634},"Clariscan",{"EARLY_PHASE1":1635,"PHASE1":1637,"PHASE2":1639,"PHASE3":1641,"PHASE4":1643,"NA":1645},{"trials":1636,"activeCount":74},[],{"trials":1638,"activeCount":74},[],{"trials":1640,"activeCount":74},[],{"trials":1642,"activeCount":74},[],{"trials":1644,"activeCount":74},[],{"trials":1646,"activeCount":74},[1647],{"nctId":1648,"briefTitle":1649,"status":259,"phases":1650,"primaryCompletion":1651,"completion":1651,"start":1652,"enrollment":1653,"conditions":1654,"interventions":1656},"NCT03455283","Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination",[],"2019-11-11","2018-12-17",2118,[1655],"Magnetic Resonance Imaging (MRI)",[1633],{"intervention":1658,"totalTrials":92,"cells":1659},"I-123 mIBG",{"EARLY_PHASE1":1660,"PHASE1":1662,"PHASE2":1664,"PHASE3":1666,"PHASE4":1668,"NA":1670},{"trials":1661,"activeCount":74},[],{"trials":1663,"activeCount":74},[],{"trials":1665,"activeCount":74},[],{"trials":1667,"activeCount":74},[],{"trials":1669,"activeCount":74},[],{"trials":1671,"activeCount":74},[1672],{"nctId":1673,"briefTitle":1674,"status":259,"phases":1675,"primaryCompletion":1418,"completion":294,"start":532,"enrollment":1676,"conditions":1677,"interventions":1678},"NCT00785044","Study Dosed With (123I-mIBG) for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event",[],471,[1160],[1658]]